Linking stressful life events and chronic inflammation using suPAR (soluble urokinase plasminogen activator receptor)

Kyle J. Bourassa a,b,1, Line J.H. Rasmussen b,c,1, Andrea Danese d,e,f, Jesper Eugen-Olsen c, HonaLee Harrington b, Renate Houts b, Richie Poulton b, Sandhya Ramrakhia b, Karen Sugden b, Ben Williams b, Terrie E. Moffitt a,b,h,1, Avshalom Caspi a,b,h,1

a Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, NC, United Kingdom
b Department of Psychology & Neuroscience, Duke University, Durham, NC, United Kingdom
c Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology, & Neuroscience, King’s College London, London, United Kingdom
d Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, United Kingdom
e Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark
f Department of Psychology, University of Otago, Otago, New Zealand
g Department of Psychology, King’s College London, London, United Kingdom
h Department of Psychiatry, Behavioral Sciences, Duke University School of Medicine, Durham, NC, United Kingdom

A R T I C L E   I N F O

Keywords:
- C-reactive protein
- Interleukin-6
- Stress
- Inflammatory biomarkers
- Adverse childhood experiences

A B S T R A C T

Stressful life events have been linked to declining health, and inflammation has been proposed as a physiological mechanism that might explain this association. Using 828 participants from the Dunedin Longitudinal Study, we tested whether people who experienced more stressful life events during adulthood would show elevated systemic inflammation when followed up in midlife, at age 45. We studied three inflammatory biomarkers: C-reactive protein (CRP), interleukin-6 (IL-6), and a newer biomarker, soluble urokinase plasminogen activator receptor (suPAR), which is thought to index systemic chronic inflammation. Stressful life events were not associated with CRP or IL-6. However, people who experienced more stressful life events from age 38 to 44 had elevated suPAR at age 45, and had significantly greater increases in suPAR from baseline to follow-up across the same period. When examining stressful life events across the lifespan, both adverse childhood experiences (ACEs) and adult stressful life events were independently associated with suPAR at age 45. ACEs moderated the association of adult stressful life events and suPAR at age 45—children with more ACEs showed higher suPAR levels after experiencing stressful life events as adults. The results suggest systemic chronic inflammation is one physiological mechanism that could link stressful life events and health, and support the use of suPAR as a useful biomarker for such research.

1. Introduction

Higher levels of psychological stress are associated with poorer subsequent health, including greater risk of developing chronic disease, accelerated disease progression, and early mortality (Cohen et al., 2007; Glaser et al., 1999; Phillips et al., 2001). This association has been documented over the course of the lifespan, in several different countries, and across a wide array of stressors, including psychological trauma, financial and relationship stress, and natural disasters (Bourassa, 2021; Browning & Heinesen, 2012; Moon et al., 2011; Niiyama et al., 2014). Similarly, exposure to adverse childhood experiences (ACEs)—emotional, physical, and sexual abuse as well as neglect, violence, and household dysfunction—is associated with increased risk of physical disease in adulthood (Kalmakis & Chandler, 2015). The pathophysiological pathways responsible for these associations, however, have been more elusive. Several mechanisms have been proposed to explain how stressful life events might affect health, such as health behaviors (Hamer et al., 2008), disruptions to homeostatic physiological processes (i.e., allostatic load; Danese & McEwen, 2012; Oken et al., 2015), and altered stress reactivity (Manuck, 1994; Carroll et al., 2017).

One physiological mechanism proposed to link stress and health is inflammation (Wirtz & von Kanel, 2017). Meta-analytic studies have
shown that acute laboratory stressors experimentally increase systemic inflammation (Marsland et al., 2017; Steptoe et al., 2007), and that chronic stressors—e.g., caregiving, socioeconomic disadvantage, and work-related stress—are associated with higher levels of systemic inflammation (Cohen et al., 2012; Rohlde, 2014; Tursich et al., 2014). Associations have also been observed between higher levels of inflammation and both socioeconomic disadvantage (Berger et al., 2019) and childhood adversity (Baumeister et al., 2016; Chen & Lacey, 2018; Danese & Baldwin, 2017), though it is notable that these associations are generally small in effect size and can vary across individual studies (Baumeister et al., 2016). Evidence that higher levels of psychological stress are associated with higher levels of systemic inflammation is particularly important given established associations between inflammation and poor health outcomes, including cardiovascular disease (Emerging Risk Factors Collaboration, 2010; Wirtz, & von Kanel, 2017), accelerated biological aging (Rasmussen et al., 2021), cancer (Guo et al., 2013), and early mortality (Möhlenkamp et al., 2011). A recent meta-analysis found that psychosocial interventions such as cognitive behavior therapy improved immune system function across a variety of outcomes, providing further evidence that immune activation or inflammation could link stress and health and act as a malleable intervention target (Shields et al., 2020).

One challenge in studying the association between stressful life events and inflammation is the measurement of systemic inflammation. A variety of biomarkers are used to assess systemic inflammation, with limited consensus on which measures are optimal to assess future health outcomes. A variety of biomarkers are used to assess systemic inflammation, for example, immune cell counts, and cytokines and as such are thought to reflect inflammation. Such inflammatory biomarkers, such as CRP (Lyngbæk et al., 2013a; Rasmussen et al., 2021), and early mortality (Möhlenkamp et al., 2011). A recent meta-analysis found that psychosocial interventions such as cognitive behavior therapy improved immune system function across a variety of outcomes, providing further evidence that immune activation or inflammation could link stress and health and act as a malleable intervention target (Shields et al., 2020).

A promising and recently validated biomarker of systemic chronic inflammation is soluble urokinase plasminogen activator receptor (suPAR)—the soluble form of the membrane-bound receptor uPAR (Desmedt et al., 2017). During proinflammatory conditions, suPAR is cleaved from the surface of immunologically active cells (e.g., macrophages, neutrophils, endothelial cells, and some cancer cells) leading to an increase in the blood concentration of suPAR. Blood suPAR levels are correlated with levels of other inflammation markers, immune cell counts, and cytokines and as such are thought to reflect overall immune activity. Elevated suPAR statistically predicts incident and prevalent disease (Hayek et al., 2020), chronic disease progression (Rasmussen et al., 2017), accelerated biological aging (Rasmussen et al., 2021), and early death due to chronic disease (Eugen-Olsen et al., 2010). Like systemic chronic inflammation (Furman et al., 2019), suPAR is non-specifically associated with a wide range of diseases, non-communicable and infectious diseases alike, including cardiovascular disease, diabetes, cancer, rheumatic disease, pneumonia, COVID-19, and sepsis (Desmedt et al., 2017; Rovina et al., 2020). Importantly, suPAR appears to be less sensitive to acute changes in health compared to other inflammatory biomarkers, such as CRP (Lynghaek et al., 2019a; Rasmussen et al., 2021), and could therefore be a better measure of systemic chronic inflammation.

Given that suPAR appears to index chronic inflammation when accounting for other measures of inflammation (e.g., CRP; Rasmussen et al., 2019a, 2019b), it presents the opportunity to examine the association between difficult life experiences and inflammation across the lifespan—e.g., from childhood to midlife—rather than focusing exclusively on recent stressful events. Cumulative, biological-embedding, and sensitization models (Young et al., 2019) present three plausible representations for how stressful life events at different developmental periods could influence later inflammation. A cumulative model would suggest stressful experiences from both childhood and adulthood would exert an independent, additive effect on later inflammation (Hostinar et al., 2015). A biological-embedding model would instead suggest stressful life events in childhood, but not adulthood, would be associated with later inflammation. Finally, a sensitization model would suggest that people who experience childhood adversity would be at greater risk of a proinflammatory response to adult stressful life events (Miller et al., 2011; Young et al., 2019). Longitudinal measurement of ACEs, stressful life events, and inflammatory biomarkers in Dunedin allow us to test which models best describe the association between stressful experiences and inflammation.

1.1. Present study

The current study used data from 828 participants in the Dunedin Longitudinal Study (Poulton et al., 2015), a population-representative birth cohort followed from birth to age 45, to examine a number of research questions related to stressful life events and systemic inflammation. Near their 38th and 45th birthdays, we drew blood from participants to assess inflammatory biomarkers and interviewed participants regarding the stressful life events they experienced in the years since the last assessment (covering, respectively, ages 32 through 37 and 38 through 44). Our analyses focused on the period from age 38 to 45, as these were the Dunedin Study occasions at which we had measures of stressful life events and assessed the three inflammatory biomarkers. We first examined whether the number of stressful life events participants experienced was associated with chronic inflammation as assessed by suPAR levels at age 45, as well as change in suPAR from age 38 to age 45. We then compared these associations to those for CRP and IL-6. We hypothesized that experiencing more stressful life events would be associated with elevated levels of inflammation. If suPAR was a better measure of chronic inflammation than CRP and IL-6, we would expect suPAR to be more strongly associated with stressful life events than CRP or IL-6. We then tested the cumulative, biological embedding, and sensitization models that might characterize the associations between inflammation and stressful life events across the lifespan. We hypothesized that adversity from earlier in the lifespan, in the form of ACEs, would moderate the association of adult stressful life events and inflammation, such that people with more ACEs would have a stronger association between stressful life events and inflammation at age 45 (i.e., a sensitization model).

2. Method

2.1. Study design and population

Participants are members of the Dunedin Study, a longitudinal investigation of a population-representative birth cohort. The 1037 participants (91% of eligible births; 52% male) were all individuals born between April 1972 and March 1973 in Dunedin, New Zealand, who were eligible based on residence in the province and who participated in the first assessment at age 3 years (Poulton et al., 2015). The cohort represented the full range of socioeconomic status (SES) in the general population of New Zealand’s South Island. As adults, the cohort matches the results from the New Zealand National Health and Nutrition Survey on key adult health indicators (Poulton et al., 2015). It matches the distribution of educational attainment among citizens of the same age from the New Zealand Census (Richmond-Rakerd et al., 2020). The cohort is predominantly white (92%), matching South Island demographics (Poulton et al., 2015). Assessments were performed at birth; at ages 3, 5, 7, 9, 11, 13, 15, 18, 21, 26, 32, 38 and, most recently at age 45 years (completed April 2019), when 938 of the 997 participants (94.1%) still alive participated. Written informed consent was obtained from participants, and the institutional review boards of the participating universities approved study protocols. Of the 938 who...
2. Measures

2.2.1. Inflammation

We assessed systemic inflammation using three biomarkers, as previously described (Rasmussen et al., 2019a, 2019b). Plasma suPAR (ng/mL) was analyzed at ages 38 and 45 with the suPARnostic AUTO Flex ELISA (ViroGates A/S, Birkerød, Denmark) according to the manufacturer’s instructions. The lower detection limit of the assay was 0.1 ng/mL. The intraassay correlation of repeat measurements of the same sample was r = 0.98 and coefficient of variation (CV) = 2.4%, and the interassay correlation was r = 0.81 and CV = 12.8%. suPAR levels were correlated at age 38 and 45, r = 0.58, p < .001, and increased on average 0.6 ng/mL from age 38 to 45, with changes ranging from −5.4 to 9.3 ng/mL.

2.2.1.2. C-reactive protein. Serum high-sensitivity CRP (hsCRP, mg/L) was measured on a Modular P analyzer (Roche Diagnostics GmbH, Mannheim, Germany) at age 38 and on a Cobas c 702 analyzer (Roche Diagnostics GmbH) at age 45, using particle-enhanced immunoturbidimetric assays. The lower detection limit of the assay was 0.3 mg/L. The intraassay and interassay CVs reported by the manufacturer were r = 0.28–1.34% and r = 2.51–5.70%, respectively. CRP increased on average 0.3 mg/L from age 38 to 45, with changes ranging from −35.6 to 88.9 mg/L. CRP values were log-transformed to account for positive skew. Transformed CRP levels were correlated at age 38 and 45, r = 0.48, p < .001. Previous research has also recommended excluding untransformed CRP values greater than 10 mg/L (Pearson et al., 2003) to account for acute infection. Notably, removing these values did not alter any of the substantive results reported in this study.

2.2.1.3. Interleukin-6. At age 38, plasma IL-6 (pg/mL) was measured on a Molecular Devices (Sunnyvale, CA) SpectraMax plus 384 plate reader using R&D Systems (Minneapolis, MN) Quantikine High-sensitivity ELISA kit HS600B according to the manufacturer’s instructions. At age 45, serum IL-6 (pg/mL) was measured on a Cobas e 602 analyzer (Roche Diagnostics GmbH), using an electrochemiluminescence immunoassay. The lower detection limit of the assay was 1.5 pg/mL. The intraassay and interassay CVs reported by the manufacturer were 2.5–6.0% and 2.9–8.5%, respectively. IL-6 increased on average 0.6 pg/mL from age 38 to 45, with changes ranging from −17.3 to 27.6 pg/mL. IL-6 values were log-transformed to account for positive skew. Transformed IL-6 levels were correlated at age 38 and 45, r = 0.45, p < .001.

2.2.2. Stressful life events

Life history calendars (Caspi et al., 1996) were used to derive a count of the number of stressful life events that participants experienced from age 32 through 37 and from 38 through 44. Participants reported the events occurring between study assessments on life history calendars at the age-38 and age-45 assessments. Stressful life events coded were (1) each relationship breakup, (2) whether someone moved frequently (10 or more moves, see Caspi et al., 2003), (3) homelessness at any time, (4) in jail at any time, (5) the death of a friend or family member, (6) a job loss, (7) experiencing a medical illness, mental illness, injury, or accident, (8) a friend or family member experiencing a medical illness, mental illness, injury, or accident, (9) legal problems, (10) a physical or sexual assault, (11) serious financial problems, (12) a natural or human-made disaster (e.g., fires, earthquakes), or (13) other. 20% of the total responses from age 38 to 44 (N = 1,442) were coded by two independent reviewers and evidenced strong interrater reliability, percent agreement = 92.2%, kappa = 0.91. Events in categories 1 to 13 were summed for each of the two study periods. These totals were then winsorized to a maximum of 30 events within each period. Participants experienced on average 5.5 stressful life events (SD = 4.6) from age 32 through 37 and 6.1 stressful life events (SD = 5.9) from age 38 through 44. The number of events during the two periods were correlated, r = 0.38, p < .001. (We also re-tested our hypotheses while excluding “medical illness, mental illness, injury, or accident” events, to rule out the possibility that observed associations between stressful life events and inflammation were due to higher rates of illness, rather than stressful life events in general. As shown in Supplemental Analyses 1, Supplemental Tables 1-4, substantive study results were unchanged when excluding this category of stressful life events.)

In addition, when examining the association of stressful life events and inflammation across the lifespan, we also included an additional measure of stressful life events covering ages 21 to 26 from a previous investigation using data from the Dunedin study (see Caspi et al., 2003). Age 21 to 26 stressful life events were assessed at age 26 with the aid of a life history calendar (Caspi et al., 1996). As described previously (Caspi et al., 2003), the 5-year reporting period covered events occurring after the 21st birthday and before the 26th birthday. Events included employment problems (long-term unemployment; being made redundant; losing a job because the company moved; being fired); financial problems (problems with debt, such as having items repossessed; not having enough money to pay for food or household expenses; lacking money for medical expenses; difficulty paying bills); housing problems (homelessness; multiple residential changes); health problems (a disabling physical illness lasting a month or more; a disabling injury); and relationship problems (being involved in a physically violent relationship; a break-up of a cohabiting, intimate relationship).

2.2.3. Prospective adverse childhood experiences (ACEs)

As previously described (Reuben et al., 2016), archival study records from the first 15 years of participants’ lives were reviewed by four independent raters to determine whether participants experienced 10 ACEs identified in the Center for Disease Control (CDC) ACE study (Centers for Disease Control and Prevention, 2016; Felitti et al., 1998): three types of abuse (physical, emotional, sexual), two types of neglect (physical, emotional), and five types of household dysfunction (incarceration of a family member, household substance abuse, household mental illness, loss of a parent, and household partner violence). The inter-rater agreement across all ACEs between the four raters averaged a kappa of 0.79 (range = 0.76–0.82; Reuben et al., 2016). Counts greater than four were recoded to four, in line with the CDC ACE study (Centers for Disease Control and Prevention, 2016). The distribution of ACEs in the Dunedin Study matched the distribution observed in the CDC study (Reuben et al., 2016). The mean count of ACEs in the sample was 1.1 events (SD = 1.2).

2.2.4. Clinical characteristics: Smoking, body mass index, and anti-inflammatory medication

Smoking and body mass index (BMI) were included as covariates as these are associated with elevated inflammation. Current smoking was reported at age 38 and age 45 by grouping the participants into four groups: non-smoker, smoking < 10, 10–19, or ≥ 20 cigarettes/day, as used in prior investigations (Rasmussen et al., 2019a). BMI (kg/m²) was measured at age 38 and age 45 years. Use of anti-inflammatory medications at the time of interview was assessed at age 45 years, as previously described (Rasmussen et al., 2021). Anti-inflammatory medications included non-steroidal anti-inflammatory drugs (NSAIDs), anti-gout medication, corticosteroids (respiratory, systemic), anti-rheumatics, prophylactic aspirin, and statins. As reported in a prior investigation (Rasmussen et al., 2021), suPAR was not associated with use of anti-inflammatory medications in this study at age 45. IL-6 similarly evidenced no significant association with anti-inflammatory medications at age 45. In contrast, CRP evidenced a positive
significant association with anti-inflammatory medications at age 45, $r = 0.09$, $p = .009$.

### 2.2.5. Childhood Covariates

Three childhood variables (Richmond-Rakerd et al., 2021) that have previously been associated with suPAR (Rasmussen et al., 2019b) were included in the study as covariates for the initial analyses at age 45: childhood SES, IQ, and self-control. Childhood SES was measured using the 6-point Elley-Irving Socioeconomic Index for New Zealand (Elley & Irving, 1976) and represented the average of the highest SES level of either parent across the assessments of cohort families from the participants’ birth through age 15. Childhood IQ was assessed by calculating mean scores for the Wechsler Intelligence Scale for Children-Revised (WISC-R) across administration at ages 7, 9, and 11 years. Childhood self-control was assessed during participants’ first decade of life using a composite measure that included observational ratings, parent and teacher ratings, and psychiatric interviews (see Richmond-Rakerd et al., 2021).

### 2.3. Data analysis

We specified three sets of multiple regression models to test our primary hypotheses. The first models examined whether the number of stressful life events participants experienced from age 38 through 44 was associated with suPAR, ln(CRP), and ln(IL-6) levels at age 45. Second, we used residualized regression to test whether the number of stressful life events from age 38 through 44 was associated with change in suPAR, CRP, and IL-6 from age 38 to age 45.

The third set of models tested the cumulative, biological embedding, and sensitization models by examining whether ACEs and the total cumulative number of adult stressful life events (ages 21 to 26 and 32 through 44) were independently associated with inflammation at age 45. We then tested whether ACEs moderated the association of stressful life events in adulthood and systemic inflammation at age 45. To create an overall assessment of stressful life events in adulthood, we standardized the measures of stressful life events from age 21 to 26, 32 to 37, and 38 to 44 and averaged the standardized variables. Similarly, to create an overall assessment of stressful life events across the lifespan, we standardized the measures of childhood ACEs and stressful life events in adulthood and averaged the standardized variables.

In all models, we first ran an unadjusted model, then a model controlling for sex, smoking, BMI, and anti-inflammatory medication. We also controlled for childhood covariates in the initial age 45 model. Models that assessed change in inflammation from age 38 to age 45 included the inflammatory marker assessed at age 38 and pre-baseline stressful life events from age 32 through 37. We report standardized regression coefficients ($\beta$) with 95% confidence intervals. To account for missing data, we used full information maximum likelihood estimation (Graham, 2009) in MPLUS version 8.3 (Muthén and Muthén, 2012). A second data analyst checked the analyses for reproducibility by deriving code from the manuscript and applying it to an original copy of the data set.

### 3. Results

Participants’ characteristics and demographic variables are reported in Table 1. Participants included in the current study ($N = 828$) did not differ significantly from other participants alive at age 45 on childhood ACEs, SES, IQ, or low self-control (see Supplemental Fig. 1). The three measures of systemic inflammation were significantly associated at age 45 (suPAR and CRP, $r = 0.27$; suPAR and IL-6, $r = 0.18$; CRP and IL-6, $r = 0.50$, all $p < .001$).

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Main Study Variables.</th>
</tr>
</thead>
<tbody>
<tr>
<td>$N = 828$</td>
<td>Mean ± SD</td>
</tr>
<tr>
<td>Sex</td>
<td>49.4% women</td>
</tr>
<tr>
<td>Childhood variables</td>
<td></td>
</tr>
<tr>
<td>No. of ACEs</td>
<td>1.0 ± 1.2</td>
</tr>
<tr>
<td>Socioeconomic status</td>
<td>3.8 ± 1.1</td>
</tr>
<tr>
<td>IQ</td>
<td>101.2 ± 13.8</td>
</tr>
<tr>
<td>Self-control</td>
<td>−0.05 ± 0.9</td>
</tr>
<tr>
<td>Age 26 assessment</td>
<td></td>
</tr>
<tr>
<td>No. of stressful life events age 21 through 26</td>
<td>1.6 ± 1.7</td>
</tr>
<tr>
<td>Age 38 assessment</td>
<td></td>
</tr>
<tr>
<td>CRP (ng/L)</td>
<td>2.4 ± 3.9</td>
</tr>
<tr>
<td>IL-6 (pg/mL)</td>
<td>1.5 ± 1.5</td>
</tr>
<tr>
<td>suPAR (ng/mL)</td>
<td>2.4 ± 0.9</td>
</tr>
<tr>
<td>No. of stressful life events age 32 through 37</td>
<td>5.5 ± 4.6</td>
</tr>
<tr>
<td>Age 45 assessment</td>
<td></td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
</tr>
<tr>
<td>Non-smokers, n (%)</td>
<td>667 (80.7%)</td>
</tr>
<tr>
<td>Smokers, n (%)</td>
<td>160 (19.3%)</td>
</tr>
<tr>
<td>Body mass index (kg/m$^2$)</td>
<td>28.5 ± 5.8</td>
</tr>
<tr>
<td>Anti-inflammatory medication use, n (%)</td>
<td>241 (29.1%)</td>
</tr>
<tr>
<td>CRP (ng/L)</td>
<td>2.7 ± 5.6</td>
</tr>
<tr>
<td>IL-6 (pg/mL)</td>
<td>2.1 ± 2.6</td>
</tr>
<tr>
<td>suPAR (ng/mL)</td>
<td>3.0 ± 1.0</td>
</tr>
<tr>
<td>No. of stressful life events age 38 through 44</td>
<td>6.1 ± 5.9</td>
</tr>
<tr>
<td>CRP and IL-6 values reported were untransformed. ACEs = adverse childhood experiences; CRP = C-reactive protein; IL-6 = interleukin-6; suPAR = soluble urokinase plasminogen activator receptor.</td>
<td></td>
</tr>
</tbody>
</table>

1 One participant was missing this variable at age 45.

#### 3.1. Are stressful life events associated with systemic inflammation at age 45?

Participants experiencing more stressful life events from age 38 through 44 had higher age-45 suPAR levels (Table 2). This association remained significant when controlling for sex, smoking, BMI, and anti-inflammatory medication use. Fig. 1 shows higher numbers of stressful life events from age 38 through 44 accompanied by higher age-45 suPAR levels.

In contrast to suPAR, participants’ stressful life events were not significantly associated with age-45 CRP or IL-6 levels in terms of bivariate associations, or when controlling for sex, smoking, BMI, and anti-inflammatory medication use (Table 2). None of the associations between stressful life events and systemic inflammation were substantively changed when further adjusting for childhood covariates (childhood SES, IQ, and self-control; Table 2).

#### 3.2. Are stressful life events associated with change in systemic inflammation from age 38 to 45?

Next, we examined whether stressful life events were associated with change in suPAR from age 38 through 45 using residualized regression. When controlling for age-38 suPAR, participants who experienced more stressful life events from age 38 through 44 evidenced significantly greater suPAR at age 45 (Table 3). This association remained significant when adjusting for sex, smoking, BMI, anti-inflammatory medication use, and the number of pre-baseline stressful life events experienced from age 32 through 37 (Table 3). Stressful life events from age 32 through 37 were also significantly associated with age-38 suPAR ($\beta = 0.13$, 95% CI [0.06, 0.20], $p < .001$), suggesting that stressful life events were associated with suPAR levels at this earlier occasion as well. Supplemental Analyses 1 presents results of the primary analyses when excluding two outliers.

In contrast, stressful life events from age 38 through 44 were not associated with change in either CRP ($\beta = 0.02$, 95% CI [-0.04, 0.08], $p = .470$) or IL-6 ($\beta = -0.02$, 95% CI [-0.08, 0.04], $p = .511$). This was also the case when controlling for sex, smoking, BMI, anti-inflammatory medication use, and stressful life events from age 32 through 37 (CRP:
3.3. Stressful life events across the lifespan

We next examined whether stressful life events across the lifespan were associated with systemic inflammation levels at age 45.

<table>
<thead>
<tr>
<th>Outcome: suPAR at age 45</th>
<th>β</th>
<th>95% CI</th>
<th>p</th>
<th>β</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>N = 828</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prospective ACEs</td>
<td>0.18</td>
<td>[0.11, 0.24]</td>
<td>&lt;</td>
<td>0.10</td>
<td>[0.04, 0.17]</td>
<td>&lt;</td>
</tr>
<tr>
<td>Adult stressful life events</td>
<td>0.19</td>
<td>[0.13, 0.26]</td>
<td>&lt;</td>
<td>0.12</td>
<td>[0.06, 0.19]</td>
<td>&lt;</td>
</tr>
<tr>
<td>Sex</td>
<td>-0.15</td>
<td>[-0.21, -0.09]</td>
<td>&lt;</td>
<td>-0.15</td>
<td>[-0.21, -0.09]</td>
<td>&lt;</td>
</tr>
<tr>
<td>Smoking at 45</td>
<td>0.28</td>
<td>[0.22, 0.34]</td>
<td>&lt;</td>
<td>0.28</td>
<td>[0.22, 0.34]</td>
<td>&lt;</td>
</tr>
<tr>
<td>BMI at 45</td>
<td>0.14</td>
<td>[0.07, 0.20]</td>
<td>&lt;</td>
<td>0.14</td>
<td>[0.07, 0.20]</td>
<td>&lt;</td>
</tr>
<tr>
<td>Anti-inflammatory medication use at 45</td>
<td>0.05</td>
<td>[-0.01, 0.11]</td>
<td>0.111</td>
<td>0.05</td>
<td>[-0.01, 0.11]</td>
<td>0.111</td>
</tr>
</tbody>
</table>

95% CI = 95% confidence interval; ACEs = adverse childhood experiences; BMI = body mass index; suPAR = soluble urokinase plasminogen activator receptor.

β = 0.03, 95% CI [-0.03, 0.09], p = .345; IL-6: β = -0.01, 95% CI [-0.07, 0.06], p = .809.

3.3.1. ACEs, stressful life events, and inflammation: biological embedding and cumulative models

To examine the cumulative and biological embedding models of stress and health across the lifespan, we tested whether ACEs (birth to age 15) and stressful life events in adulthood (ages 21 to 26 and 32 through 44) were independently associated with age-45 suPAR levels. In bivariate models, ACEs (β = 0.21, 95% CI [0.15, 0.28], p < .001) and stressful life events in adulthood (β = 0.23, 95% CI [0.16, 0.29], p < .001) were both associated with age-45 suPAR. In a multivariate model, ACEs and stressful life events in adulthood were also independently associated with age-45 suPAR (Table 4). These associations remained when including sex, smoking, BMI, and anti-inflammatory medication use (Table 4). When ACEs and adult stressful life events were combined into a single measure, people with more stressful life events across the lifespan evidenced higher levels of age-45 suPAR (β = 0.28, 95% CI [0.21, 0.34], p < .001), and this association remained when controlling for sex, smoking, BMI, and anti-inflammatory medication use (β = 0.17, 95% CI [0.10, 0.23], p < .001). This pattern of results suggests a cumulative effect of stressful life events, rather than biological embedding model.

We next tested these models with CRP at age 45 as the outcome. In bivariate models, stressful life events in adulthood (β = 0.08, 95% CI [0.01, 0.15], p = .023) were associated with age-45 CRP, whereas ACEs were not (β = 0.06, 95% CI [-0.01, 0.13], p = .069). In a multivariate model including both ACEs and adult stressful life events, stressful life events in adulthood remained associated with age-45 CRP (β = 0.07, 95% CI [0.00, 0.14], p = .047). However, stressful life events in adulthood were no longer significantly associated with CRP at age 45 when controlling for sex, smoking, BMI, and anti-inflammatory medication use (β = 0.03, 95% CI [-0.03, 0.09], p = .313). Similarly, people with more stressful life events across the lifespan evidenced relatively greater CRP at age 45 (β = 0.09, 95% CI [0.03, 0.16], p = .007), however this association was no longer significant when controlling for sex, smoking, BMI, and anti-inflammatory medication use (β = 0.02, 95% CI [-0.05, 0.08], p = .612).

Finally, we tested models with IL-6 at age 45 as the outcome. In bivariate models, neither ACEs (β = 0.04, 95% CI [-0.03, 0.11], p = .285), nor stressful life events in adulthood (β = 0.02, 95% CI [-0.05, 0.09], p = .543), were significantly associated with age-45 IL-6. These associations remained non-significant in a multivariate model including both ACEs and stressful life events in adulthood and when including sex, smoking, BMI, and anti-inflammatory medication use. People with more stressful life events across the lifespan did not evidence significantly greater IL-6 at age 45 (β = 0.04, 95% CI [-0.03, 0.11], p = .239), and this association remained non-significant when controlling for sex, smoking, BMI, and anti-inflammatory medication use (β = -0.02, 95% CI [-0.08, 0.05], p = .625).

3.3.2. Do ACEs sensitize people to stressful life events in adulthood?

Next, to test the sensitization model we examined whether ACEs moderated the association between adult stressful life events and suPAR levels. We observed a significant interaction, such that the more ACEs a participant had experienced in childhood the stronger the association between stressful life events in adulthood and age-45 suPAR (Table 5).
suggest that ACEs could sensitize people to pro-inflammatory effects of medication use (ACEs (BMI, and anti-inflammatory medication use (Table 5). When splitting significant when controlling for sex, smoking, BMI, and anti-inflammatory medication use (suPAR at 45 and adult stressful life events was stronger among people who had experienced more ACEs in childhood. The interaction remained significant when controlling for sex, smoking, BMI, and anti-inflammatory medication use (β = 0.07, 95% CI [0.01, 0.13], p = .027). As with suPAR, the association between stressful life events in adulthood and IL-6 at age 45 was stronger among people who experienced more ACEs in childhood.

3.4. Additional Analyses: Stressful life events across the lifespan and childhood protective Factors

At the request of the reviewers, we also investigated whether the childhood covariates (childhood SES, IQ, and self-control) might moderate the association of stressful life events across the lifespan (combining ACEs and stressful life events in adulthood) and inflammation at age 45. Childhood IQ did not moderate the association between lifetime stressful life events and age-45 suPAR (β = -0.04, 95% CI [-0.11, 0.02], p = .219), whereas both childhood self-control (β = 0.09, 95% CI [0.03, 0.16], p = .006) and childhood SES did (β = -0.14, 95% CI [-0.22, -0.07], p < .001). People with less self-control as children had a stronger association between lifetime stressful life events and age-45 suPAR. Similarly, people who grew up in homes with lower SES had a stronger association between lifetime stressful life events and age-45 suPAR. These associations remained when controlling for sex, smoking, BMI, and anti-inflammatory medication use (low self-control: β = 0.08, 95% CI [0.02, 0.15], p = .019; childhood SES: β = -0.12, 95% CI [-0.19, -0.05], p = .001). None of the childhood covariates moderated the association of lifetime stressful life events with CRP or IL-6 at age 45.

4. Discussion

The current study examined the association between stressful life events and systemic inflammation using a sample of 828 adults from the Dunedin Study. The findings indicated that people who experienced a greater number of stressful life events evidenced higher midlife systemic inflammation, in the form of elevated suPAR. These associations included both suPAR levels at age 45, as well as increases in suPAR from age 38 to 45. In contrast, no associations were observed between stressful life events and CRP or IL-6. The results suggest that systemic chronic inflammation as assessed by suPAR warrants more attention in the study of stressful life events and ill health. Measures of chronic

Finally, we tested models with IL-6 at age 45 as the outcome. We observed a significant interaction, such that the more ACEs a participant had experienced in childhood the stronger the association between stressful life events from age 32 through 44 and age-45 IL-6 (β = 0.09, 95% CI [0.02, 0.16], p = .011). The interaction remained significant when controlling for sex, smoking, BMI, and anti-inflammatory medication use (β = 0.07, 95% CI [0.01, 0.13], p = .027). As with suPAR, the association between stressful life events in adulthood and IL-6 at age 45 was stronger among people who experienced more ACEs in childhood.

Stressful life events in adulthood included stressful life events from age 21 to 26, 32 to 37, and 38 to 44. 95% CI = 95% confidence interval; ACEs = adverse childhood experiences; BMI = body mass index; suPAR = soluble urokinase plasminogen activator receptor.

The interaction remained significant when controlling for sex, smoking, BMI, and anti-inflammatory medication use (Table 5). When splitting the sample into those with no ACEs (n = 351), one ACE (n = 261), or multiple ACEs (2+; n = 216), the strength of the association between suPAR at 45 and adult stressful life events was stronger among people who had experienced more ACEs—people without ACEs (β = 0.14, p = .009), people with one ACE (β = 0.15, p = .016), people with multiple ACEs (β = 0.28, p < .001). These associations are presented in Fig. 2 and suggest that ACEs could sensitise people to pro-inflammatory effects of stressful life events in adulthood.

We next tested these models with CRP at age 45 as the outcome. We observed a significant interaction, such that the more ACEs a participant had experienced in childhood the stronger the association between stressful life events in adulthood and age-45 CRP (β = 0.08, 95% CI [0.01, 0.15], p = .032). However, this interaction was no longer significant when controlling for sex, smoking, BMI, and anti-inflammatory medication use (β = 0.03, 95% CI [-0.03, 0.10], p = .271).

Table 5

<table>
<thead>
<tr>
<th>Outcome: suPAR at age 45</th>
<th>β</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>N = 828</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prospective ACEs</td>
<td>0.16</td>
<td>[0.09,</td>
<td>&lt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.23</td>
<td>0.01</td>
</tr>
<tr>
<td>Adult stressful life</td>
<td>0.17</td>
<td>[0.11,</td>
<td>&lt;</td>
</tr>
<tr>
<td>events</td>
<td></td>
<td>0.24</td>
<td>0.01</td>
</tr>
<tr>
<td>Prospective ACEs × Adult</td>
<td>0.13</td>
<td>[0.06,</td>
<td>&lt;</td>
</tr>
<tr>
<td>Stressful Life Events</td>
<td></td>
<td>0.19</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Stressful life events in adulthood included stressful life events from age 21 to 26, 32 to 37, and 38 to 44. 95% CI = 95% confidence interval; ACEs = adverse childhood experiences; BMI = body mass index; suPAR = soluble urokinase plasminogen activator receptor.
childhood and adulthood appear to exert a cumulative, additive effect association with stressful life events in adulthood. Stressful events in events in childhood, in the form of ACEs, was associated with increased sensitization models (Young et al., 2019). Experiencing stressful life later inflammation, we found the most support for the cumulative and — adversity life events could also suggest the unique importance of childhood association with inflammation even when accounting for adult stressful contexts, suPAR adverse childhood experiences (ACEs) experienced in childhood (0, 1, and 2 +). Two outliers in suPAR described in the main text are not included. SD = standard deviation.

inflammation such as suPAR could represent cumulative inflammation over the course of years and provide utility in life course and cohort research studies that assess individuals over years and decades. In such contexts, suPAR’s stability over time could make it useful as an inflammatory biomarker, particularly when assessing responses to chronic stressors.

When testing the timing of stressful life events across the lifespan and later inflammation, we found the most support for the cumulative and sensitization models (Young et al., 2019). Experiencing stressful life events in childhood, in the form of ACEs, was associated with increased suPAR in midlife. Notably, this association was above and beyond the association with stressful life events in adulthood. Stressful events in childhood and adulthood appear to exert a cumulative, additive effect on suPAR in midlife, though the fact that ACEs continued to evidence an association with inflammation even when accounting for adult stressful life events could also suggest the unique importance of childhood adversity—more in line with a biological embedding model. ACEs also appeared to sensitize people to later stressful life events, such that people who experienced more ACEs evidenced higher levels of suPAR in response to stressful life events compared to those who did not. These results suggest that childhood adversity is associated with heightened inflammatory responses decades later, matching previous research from this sample (Danese et al., 2007) and highlighting the relevance of assessing stressful life events across the lifespan.

These results have theoretical, methodological, and clinical implications. Theoretically, the results suggest that systemic inflammation might be one biological pathway through which stressful life events become embedded within people’s physiology to affect downstream health. A number of behavioral and physiological pathways have been proposed to explain the association between stressful life events and health. For example, people who experience stressful life events, such as trauma and divorce, are more likely to smoke, less likely to engage in physical activity (Bourassa et al., 2019; Feldner et al., 2007; Zen et al., 2012), and more likely to evidence poor cardiovascular functioning following such events (Bourassa et al., 2016; Buckley et al., 2004; Pole, 2007). Systemic inflammation may complement or work in concert with such pathways to result in poorer health. For example, higher levels of inflammation can contribute to poorer cardiovascular health (Emerging Risk Factors Collaboration, 2010), and may explain why people who experience trauma and develop PTSD are at greater risk for cardiovascular disease and early mortality (Boscarino, 2008; Edmondson & von Känel, 2017).

In terms of methodological implications, the current results suggest that it may be useful to assess systemic inflammation using chronic inflammatory biomarkers, such as suPAR. The traditional inflammatory biomarkers included in this study—CRP and IL-6—did not evidence consistent associations with stressful life events, which stands in contrast to previous findings showing associations between traumatic and stressful life events with CRP and IL-6 (Baumeister et al., 2016; Chen & Lacey, 2018; Danese & Baldwin, 2017). However, research in this field has not always yielded consistent results, with some studies reporting non-significant associations for CRP or IL-6 with stress and traumatic experiences (Baumeister et al., 2016; Chiang et al., 2019; Hartwell et al., 2013; Low et al., 2013). One possible explanation is that these traditional biomarkers of inflammation may mix chronic and acute effects due to their sensitivity to short-term influences and involvement in the acute-phase response. High variability could result in mixed findings across studies if the underlying associations are small in size, as some meta-analyses have found (Baumeister et al., 2016). Currently, there are no standard biomarkers for measuring systemic chronic inflammation, which is inadequately measured by combining canonical biomarkers of acute inflammation (Furman et al., 2019). suPAR is generated under proinflammatory conditions through cleavage and shedding of uPAR (Thun et al., 2009) and appears to be more stable, less sensitive to acute changes and circadian rhythm, and less rapidly up- and down-regulated (Andersen et al., 2008; Lyngbæk et al., 2013b). This stability could make suPAR better suited to index underlying chronic inflammation.

Although additional replication is needed, these results suggest suPAR may be a useful biomarker with which to investigate the association between stressful events and health. This is particularly relevant given the established associations linking suPAR to poorer health (Botha et al., 2015; Eugen-Olsen et al., 2010; Persson et al., 2014; Rasmussen et al., 2021). Importantly, we have previously shown that suPAR is elevated in individuals who have been exposed to early-life stress even in the absence of elevated CRP or IL-6 in this cohort and the UK E-Risk cohort (Rasmussen et al., 2019a). suPAR remained associated with accelerated aging, physical, and cognitive decline (Rasmussen et al., 2021), and mortality, even after adjustment for CRP or IL-6 (Rasmussen et al., 2016; Botha et al., 2015). However, we also observed the strongest associations between early-life stress and inflammation when utilizing all three biomarkers to maximize information yield on inflammation (Rasmussen et al., 2019a). Future studies could provide additional information as to whether combining suPAR with other inflammatory markers or if using suPAR independently provides the most research and clinical utility in the study of stressful life events.
Clinically, these results highlight that systemic inflammation is a potential intervention target to improve health for people under stress. Behavioral interventions that reduce people’s psychological distress following trauma or other stressors might be able to reduce inflammation and improve people’s health as a result (Shields et al., 2020). Changes in systemic inflammation might also serve as a useful surrogate endpoint in intervention studies seeking to reduce poor health among people who experience stressful life events (Moffitt and the Klaus-Grave, 2012). Establishing the potential for interventions to improve health following stressful life events would require the inclusion of biomarkers, such as suPAR, in future behavioral intervention studies for people who experience stressful life events to provide evidence of reversibility (see Malarkey et al., 2013; Thornton et al., 2009; VillaIba et al., 2019).

The results of this study should be understood within the context of its limitations. First, the current study used data from a longitudinal cohort study assessed from birth to age 45, but all three inflammatory biomarkers were only assessed at ages 38 and 45. Future replication of these results at the age-52 Dunedin follow-up would provide additional confidence in our findings. Similarly, the sample is predominantly composed of New Zealanders of European ancestry. Replications in more diverse populations are needed. Second, the current study assessed stressful life events using a coding system that provided a count of events, but did not assess the degree to which identified events were stressful to individuals. It is possible that the timing, salience, or type of stressful event may have played a role in the observed association. Similarly, although the study includes stressful life events across every decade from birth to age 45, at least in part, there are period of time that do not have stressful life events assessed. Future studies would benefit from assessing stressful life events at each study occasion. In addition, ACEs and adult stressful life events were assessed using different methods, which may have affected the results. Third, the distributional properties of suPAR are appealing for research purposes, but the optimal threshold for its use as a clinical biomarker has not yet been determined, limiting clinical utility. Finally, the current study was an observational study and cannot rule out non-causal alternative explanations.

4.1. Conclusions

The findings from the current study suggest suPAR could be a particularly useful inflammatory biomarker with which to investigate the association between chronic stressors and systemic inflammation. The association between stressful life events and inflammation was particularly strong among people who had experienced ACEs in childhood, suggesting that the timing of stressful life events across the life-span has relevance to inflammation in midlife.

Note: The Dunedin Multidisciplinary Health and Development Research Unit is supported by the New Zealand Health Research Council and New Zealand Ministry of Business, Innovation and Employment (MBIE). The Dunedin Study received support from the US-National Institute on Aging [grants R01AG032282, P30AG028716, P30AG034424] and the UK Medical Research Council [grant MR/P005918/1]. KJB received support from the National Institute on Aging P30AG034424] and the UK Medical Research Council [grant MR/KB18754/1. The Dunedin Study received support from the US-National and New Zealand Ministry of Business, Innovation and Employment Research Unit is supported by the New Zealand Health Research Council.

Declaration of Competing Interest

JEO is a named inventor on patents on suPAR as a prognostic biomarker. The patents are owned by Copenhagen University Hospital Amager and Hvidovre, Denmark, and is licensed to ViroGates A/S. J.E.-O. is a co-founder, shareholder, and CSO of ViroGates A/S. The remaining authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.bbi.2021.06.018.

References


